Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2007-05-01
2007-05-01
Bernhardt, Emily (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C544S360000
Reexamination Certificate
active
11376042
ABSTRACT:
The present invention relates to compounds of formula IwhereinR is methyl; andR1is 4-methyl-4-oxy-piperazin-1-yl; orR is CH2OH andR1is 4-methyl-piperazin-1-yl or is 4-methyl-4-oxy-piperazin-1-yl;and to pharmaceutically acceptable acid addition salts thereof for the treatment of NK-1 receptor related diseases, for example depression, Parkinson's disease, Alzheimer's disease, anxiety, emesis, and pain.
REFERENCES:
patent: 5972938 (1999-10-01), Rupniak et al.
patent: 6479482 (2002-11-01), Bos et al.
patent: 6593472 (2003-07-01), Hoffmann et al.
patent: 2003/0083345 (2003-05-01), Hoffmann et al.
patent: 2005/0090533 (2005-04-01), Hoffmann et al.
patent: 10008042 (2000-08-01), None
patent: 1 035 115 (2000-09-01), None
patent: 1 103 545 (2001-05-01), None
patent: WO 95/16679 (1995-06-01), None
patent: WO 95/18124 (1995-07-01), None
patent: WO 95/23798 (1995-09-01), None
patent: WO 2005/002577 (2005-01-01), None
Barker, R., Reviews in the Neuroscieces, vol. 7, pp. 187-214 (1996).
Longmore, et al., Can. J. Physiol. Pharmacol. vol. 75, pp. 612-621 (1997).
Kramer, et al., Science, vol. 281, pp. 1640-1645 (1998).
Maggi, et al., J. Auton. Pharmacol. vol. 13, pp. 23-93 (1993).
Navari, et al., The New England Journal of Medicine, vol. 340, No. 3, pp. 190-195 (1999).
Halliwell et al., Toxicologic Pathology, vol. 25(1), pp. 53-60 (1997).
Lullmann, et al., Biochemical Pharmacology, vol. 27, pp. 1103-1108 (1978).
Funk Christoph
Hoffmann Torsten
Koblet Andreas
Bernhardt Emily
Hoffmann-La Roche Inc.
Johnston George W.
Prior Kimberly J.
Rocha-Tramaloni Patricia S.
LandOfFree
NK-1 receptor antagonists does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with NK-1 receptor antagonists, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and NK-1 receptor antagonists will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3770891